Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196495 | 1.00 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| Hydrochloric Acid SCHEMBL4527827 | 0.98 | CYP3A4 (0.32) | CYP3A4TDP1TAAR1 | |
| SCHEMBL613867 | 0.98 | CYP3A4 (0.35) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL613866 | 0.98 | CYP3A4 (0.35) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL3310231 | 0.98 | CYP3A4 (0.35) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL5177211 | 0.96 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| Hydrochloric Acid SCHEMBL7834687 | 0.94 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL9740749 | 0.94 | CYP3A4 (0.32) | CYP3A4TDP1TAAR1 | |
| Hydrochloric Acid SCHEMBL4527828 | 0.94 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL10627872 | 0.94 | CYP3A4 (0.32) | CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| EP-2358675-B9 | 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190134019-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10206913-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180289687-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-11 | — | — | US | disclosed |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180050024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-7777077-B2 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| WO-2010056941-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2132187-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090239904-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090182010-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-16 | — | — | US | disclosed |
| WO-2008097459-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
| EP-1833822-A2 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006023460-A2 | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20090182010-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRA2B, ADRA2A | CYP3A4 1383/4885TDP1 4531/4885TAAR1 95/4885 |
| US-20180289687-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20180050024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20190134019-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | CYP3A4 1115/4885TDP1 3813/4885TAAR1 101/4885 |
| US-10206913-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | CYP3A4 115/4885TDP1 2084/4885TAAR1 74/4885 |
| US-20090239904-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRA2B, ADRB2, ADRB1 | CYP3A4 1734/4885TDP1 4682/4885TAAR1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.